CTSH three-lens brief
Evidence-based stock research on CTSH. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Trading at 13% of its 52-week range — deep in the lower band.
- Trading at 13% of its 52-week range — deep in the lower band.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 18.1pp over 30 days.
- P/E of 9.5 — trading at a value multiple.
- Analyst mean target $67.14 — 53% above current (25 analysts).
CTSH closed at $43.76 (+0.83%) as of 2026-07-10. Market cap: $20.70B. P/E (trailing) 9.5. Price is below the 50-day MA and below the 200-day MA. Positives: p/E of 9.5 — trading at a value multiple.; analyst mean target $67.14 — 53% above current (25 analysts).. Concerns: trading at 13% of its 52-week range — deep in the lower band.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $5.41B, net income $662.00M, free cash flow $1.91B. Watching for: 2026-07-29 earnings release (18 days out).
Why three lenses on CTSH, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CTSHacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CTSH" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CTSH brief"></iframe>